Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) today announced that it has submitted a supplemental new drug application for mirogabalin besilate (hereinafter, mirogabalin) for an additional indication related to central neuropathic pain (CNP) 1in Japan.

This application is based on the results from a phase 3 trial conducted in patients with CNP.

Daiichi Sankyo will continue to strive to provide new therapeutic options for patients suffering from diverse types of pain.

Mirogabalin is created by Daiichi Sankyo for the treatment of chronic pain. The drug is considered to exhibit an analgesic action by suppressing the increased release of neurotransmitters in nerve endings involved in pain. Approval for the indication of peripheral neuropathic pain was obtained in January 2019 in Japan.

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”